Sensorion Announces New Positive Clinical Data from Its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris Page 1

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specialized in the development of novel therapies to restore, treat and prevent hearing loss in the field of hearing loss disorders, today announced positive new medical data from its clinical programs SENS-501 and SENS-401 during a symposium (12:30-13:30 CET) and in an oral presentation on SENS-401 (11:15 CET) organized as part of the 36^and World Congress of Audiology (WCA), held in Paris at the CNIT, La Défense, France.

The company today reports new data from its pipeline of gene therapy (SENS-501) and small molecule (SENS-401) programs. Details of these medical advances are presented by Professor
Natalie LoundonENT surgeon at the Necker-Enfants Children’s Hospital in Paris, France, Professor Catherine Birman (Ear, Nose and Throat Specialist, Director of the Sydney Cochlear Implant Centre, Australia), Professor Yann Nguyen (ENT Surgeon, Pitié Salpétrière Hospital, Paris, France), Professor Stephen O’Leary (Head of the Department of Otorhinolaryngology, University of Melbourne, Australia) and Professor Christophe Vincent (Head of Otology and Otoneurology Department, ENT Specialist, Salengro Hospital, Lille, France).